Home>>Signaling Pathways>> Immunology/Inflammation>> Interleukin Related>>Suramin hexasodium salt

Suramin hexasodium salt Sale

(Synonyms: 苏拉明钠; Suramin hexasodium salt) 目录号 : GC16832

A polysulfonated naphthylurea with antiviral, antiparasitic, and anticancer activities

Suramin hexasodium salt Chemical Structure

Cas No.:129-46-4

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥1,617.00
现货
25mg
¥1,470.00
现货
50mg
¥2,352.00
现货
100mg
¥3,763.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Cell experiment [1]:

Cell lines

Vero E6 and Calu-3

Preparation Method

Vero E6 and Calu-3 cells were preincubated for 30 min with 2-fold serial dilutions of a starting concentration of 200 μM Suramin hexasodium salt and subsequently infected with 2 × 104 PFU of SARS-CoV-2 (MOI of 1 on Vero E6 cells) in 50 μl medium with compound.

Reaction Conditions

200μM for 16 hours or 21 hours

Applications

RT-qPCR revealed that the SARS-CoV-2 RNA levels decreased upon Suramin hexasodium salt treatment in a dose-dependent manner, showing a 3-log reduction at the highest concentration tested (200 μM)

Animal experiment [2]:

Animal models

C57BL/6JNarl (B6) mice

Preparation Method

Suramin hexasodium salt was diluted in normal saline, and indicated doses were administered at 4 h pre-infection, 1day post-infection or/and 3day post-infection (dpi) via the intraperitoneal (ip) route. Specifically, each dose comprised 0, 0.25, 0.5, 1 or 2 mg suramin hexasodium salt.

Dosage form

Intraperitoneal injection, 0, 0.25, 0.5, 1 or 2 mg

Applications

Viral loads in sera of mock-treated mice infected with the 0810bTw, 0611aTw and 0706aTw CHIKV strains at the 2 dpi peak were 5.8, 3 and 4.2 Log10 CCID50/ml, respectively (Fig. 2A). To parallel, viral titers of suramin hexasodium salt-treated sera after received two doses (pre 4 h and 1 dpi) were 5, 2.5 and 3.8 Log10 CCID50/ml for 0810bTw, 0611aTw and 0706aTw strains, respectively.

References:

[1]. Salgado-Benvindo, C., Thaler, M., Tas, A., Ogando, N. S., et al. Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle. 2020. Antimicrob. Agents Chemother. 20, DOI: 10.1128/AAC.00900-20.

[2]. Kuo SC, Wang YM, Ho YJ, Chang TY, Lai ZZ, Tsui PY, Wu TY, Lin CC. 2016. Suramin treatment reduces chikungunya pathogenesis in mice. Antiviral Res 134:89–96.

产品描述

Suramin hexasodium salt is a polysulfonated naphthylurea with various biological activities. Suramin hexasodium salt is a DNA topoisomerase II inhibitor with an IC50 of 5 μM [1].

Suramin hexasodium salt at 300–600 μg/ml significantly inhibited HO-8910 PM and HeLa cell growth at 24 h, in both a time-dependent and dose-dependent manner, with an IC50 of 320 μg/ml and 475 μg/ml, respectively. Suramin hexasodium salt at 300 μg/ml significantly decreased the expression of Hpa mRNA (P?<?0.005) and protein (P?<?0.005) in both HO-8910 PM and HeLa cells at 48 h [2]. Suramin hexasodium salt shows antiviral activity against the newly emerged virus strain SARS-CoV-2 [3,4].Solution based assays of RdRp inhibition determined that the half-maximal inhibition concentration (IC50) of suramin hexasodium salt is 0.26?μM, Cell-based experiments indicated that suramin hexasodium salt was able to inhibit SARS-CoV-2 duplication in Vero E6 cells with a half-maximal effective concentration (EC50) of roughly 2.9?μM [3].Suramin hexasodium salt treatment of infected Vero E6 cells led to a reduction in extracellular viral RNA levels of up to 3 log. The highest concentration of compound that was used proved harmless to the cells; also, cytotoxicity was observed previously only above 5?mM. Suramin hexasodium salt also displayed antiviral efficacy in a human lung epithelial cell line, and we observed a >2 log reduction in levels of infectious virus progeny in suramin hexasodium salt -treated cells (CC50/EC90?=?>55) [4].

Suramin hexasodium salt has therapeutic effects on CHIKV-infected mice. Suramin hexasodium salt treatment ameliorated foot swelling and reduced inflammatory infiltration, which corresponded to reduced viremia and viral antigen expression in infected tissues. Suramin hexasodium salt induces a dose-dependent reduction in foot swelling in CHIKV 0810bTw-infected mice, and the vary degrees of decreased viremia that was detected in suramin hexasodium salt -treated mice further confirmed therapeutic effects of this drug. In the time-related assay, a single dose of 2 mg suramin hexasodium salt (at 4 h pre-infection) or double doses of 2 mg suramin hexasodium salt (at 1 dpi and 3 dpi) significantly decreased disease score and viremia compared to mock-treated mice.

References:
[1]. Bojanowski K, et al. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcomacells. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3025-9.
[2]. Li, H.; Li, H.; Qu, H.; et al. Suramin inhibits cell proliferation in ovarian and cervical cancer by downregulating heparanase expression. Cancer Cell Int. 2015, 15, 1–11
[3]. Yin, W. et al. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin. Nat. Struct. Mol. Biol. 28, 319–325 (2021).
[4]. Salgado-Benvindo, C., Thaler, M., Tas, A., Ogando, N. S., et al. Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle. 2020. Antimicrob. Agents Chemother. 20, DOI: 10.1128/AAC.00900-20
[5]. Kuo SC, Wang YM, Ho YJ, Chang TY, Lai ZZ, Tsui PY, Wu TY, Lin CC. 2016. Suramin treatment reduces chikungunya pathogenesis in mice. Antiviral Res 134:89–96.

苏拉明六钠盐是一种具有多种生物活性的多磺化萘脲。 Suramin hexasodium salt 是一种 DNA 拓扑异构酶 II 抑制剂,IC50 为 5 μM [1]

300-600 μg/ml 的苏拉明六钠盐在 24 小时内以时间依赖性和剂量依赖性方式显着抑制 HO-8910 PM 和 HeLa 细胞的生长,IC50分别为 320 μg/ml 和 475 μg/ml。 300 μg/ml 苏拉明六钠盐显着降低 HO-8910 PM 和 HeLa 细胞在 48 h 时 Hpa mRNA (P><>0.005) 和蛋白质 (P><>0.005) 的表达[2]。苏拉明六钠盐对新出现的病毒株 SARS-CoV-2 [3,4] 显示出抗病毒活性。基于溶液的 RdRp 抑制测定确定了半数最大抑制浓度 (IC50 ) 的苏拉明六钠盐为 0.26 μM,基于细胞的实验表明,苏拉明六钠盐能够以半数最大有效浓度 (EC50< /sub>) 大约为 2.9μM [3]。苏拉明六钠盐处理受感染的 Vero E6 细胞导致细胞外病毒 RNA 水平降低高达 3 log。使用的最高浓度的化合物被证明对细胞无害;此外,以前仅在 5mM 以上观察到细胞毒性。苏拉明六钠盐在人肺上皮细胞系中也显示出抗病毒功效,我们观察到苏拉明六钠盐处理的细胞中感染性病毒后代水平的 >2 log 降低 (CC50/EC90 = >55) [ 4].

苏拉明六钠盐对感染 CHIKV 的小鼠具有治疗作用。苏拉明六钠盐治疗改善了足部肿胀并减少了炎症浸润,这对应于受感染组织中病毒血症和病毒抗原表达的减少。苏拉明六钠盐诱导 CHIKV 0810bTw 感染小鼠足部肿胀的剂量依赖性减少,并且在苏拉明六钠盐处理的小鼠中检测到的不同程度的病毒血症减少进一步证实了该药物的治疗效果。在与时间相关的测定中,单剂量 2 mg 苏拉明六钠盐(在感染前 4 小时)或双剂量 2 mg 苏拉明六钠盐(在 1 dpi 和 3 dpi)与模拟相比显着降低疾病评分和病毒血症-治疗小鼠。

Chemical Properties

Cas No. 129-46-4 SDF
别名 苏拉明钠; Suramin hexasodium salt
化学名 sodium 8,8'-((3,3'-((3,3'-(carbonylbis(azanediyl))bis(benzoyl))bis(azanediyl))bis(4-methylbenzoyl))bis(azanediyl))bis(naphthalene-1,3,5-trisulfonate)
Canonical SMILES [O-]S(=O)(C1=C(C(NC(C2=CC=C(C)C(NC(C3=CC=CC(NC(NC4=CC(C(NC5=CC(C(NC(C(C6=CC(S([O-])(=O)=O)=C7)=C7S([O-])(=O)=O)=CC=C6S([O-])(=O)=O)=O)=CC=C5C)=O)=CC=C4)=O)=C3)=O)=C2)=O)=CC=C8S([O-])(=O)=O)C8=CC(S([O-])(=O)=O)=C1)=O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
分子式 C51H34N6Na6O23S6 分子量 1429.15
溶解度 > 71.45mg/mL in Water; > 50mg/mL in DMSO 储存条件 4°C, protect from light
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 0.6997 mL 3.4986 mL 6.9972 mL
5 mM 0.1399 mL 0.6997 mL 1.3994 mL
10 mM 0.07 mL 0.3499 mL 0.6997 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin

Nat Struct Mol Biol2021 Mar;28(3):319-325.PMID: 33674802DOI: 10.1038/s41594-021-00570-0

The COVID-19 pandemic caused by nonstop infections of SARS-CoV-2 has continued to ravage many countries worldwide. Here we report that suramin, a 100-year-old drug, is a potent inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and acts by blocking the binding of RNA to the enzyme. In biochemical assays, suramin and its derivatives are at least 20-fold more potent than remdesivir, the currently approved nucleotide drug for treatment of COVID-19. The 2.6 Å cryo-electron microscopy structure of the viral RdRp bound to suramin reveals two binding sites. One site directly blocks the binding of the RNA template strand and the other site clashes with the RNA primer strand near the RdRp catalytic site, thus inhibiting RdRp activity. Suramin blocks viral replication in Vero E6 cells, although the reasons underlying this effect are likely various. Our results provide a structural mechanism for a nonnucleotide inhibitor of the SARS-CoV-2 RdRp.

Suramin

Cancer Pract1995 May-Jun;3(3):187-9.PMID: 7599677DOI: 10.1016/0305-7372(94)90003-5

In 2021, we commemorate the 40th anniversary of the identification of the disease AIDS, the acquired immune deficiency syndrome, a name that for the first time in history was launched in 1981 [...].

Suramin

Cancer Treat Rev1994 Jul;20(3):259-73.PMID: 8020006DOI: 10.1016/0305-7372(94)90003-5

In 2021, we commemorate the 40th anniversary of the identification of the disease AIDS, the acquired immune deficiency syndrome, a name that for the first time in history was launched in 1981 [...].

1984-Discovery of the First Anti-HIV Drug, Suramin

Viruses2021 Aug 19;13(8):1646.PMID: 34452510DOI: 10.3390/v13081646

In 2021, we commemorate the 40th anniversary of the identification of the disease AIDS, the acquired immune deficiency syndrome, a name that for the first time in history was launched in 1981 [...].

Targeted Redesign of Suramin Analogs for Novel Antimicrobial Lead Development

J Chem Inf Model2021 Sep 27;61(9):4442-4454.PMID: 34516120DOI: 10.1021/acs.jcim.1c00578

The emergence of new viral infections and drug-resistant bacteria urgently necessitates expedient therapeutic development. Repurposing and redesign of existing drugs against different targets are one potential way in which to accelerate this process. Suramin was initially developed as a successful antiparasitic drug but has also shown promising antiviral and antibacterial activities. However, due to its high conformational flexibility and negative charge, suramin is considered quite promiscuous toward positively charged sites within nucleic acid binding proteins. Although some suramin analogs have been developed against specific targets, only limited structure-activity relationship studies were performed, and virtual screening has yet to be used to identify more specific inhibitor(s) based on its scaffold. Using available structures, we investigated suramin's target diversity, confirming that suramin preferentially binds to protein pockets that are both positively charged and enriched in aromatic or leucine residues. Further, suramin's high conformational flexibility allows adaptation to structurally diverse binding surfaces. From this platform, we developed a framework for structure- and docking-guided elaboration of suramin analog scaffolds using virtual screening of suramin and heparin analogs against a panel of diverse therapeutically relevant viral and bacterial protein targets. Use of this new framework to design potentially specific suramin analogs is exemplified using the SARS-CoV-2 RNA-dependent RNA polymerase and nucleocapsid protein, identifying leads that might inhibit a wide range of coronaviruses. The approach presented here establishes a computational framework for designing suramin analogs against different bacterial and viral targets and repurposing existing drugs for more specific inhibitory activity.